Reason for request
Indication extension
Summary of opinion
Favourable opinion for reimbursement in the following indication: “KEYTRUDA, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of KEYTRUDA (pembrolizumab), in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is substantial in the indication: “in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
|
Clinical Added Value
| moderate |
Considering:
- demonstration in a randomised, double-blind, phase 3 study (KN-A18 trial, including 56.7% FIGO 2014 stage III - IVA patients) of the superiority of pembrolizumab compared to chemoradiotherapy, for the treatment of FIGO stage IB2-IIB and III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy, in terms of:
- progression-free survival with an HR = 0.70 (95% CI = [0.55; 0.89]; p = 0.002 < the predefined threshold of 0.0172), 7% patients progressed or died in the experimental group versus 29.0% patients in the control group. The median PFS was not reached in either of the two groups.
- overall survival with an HR = 0.67 (95% CI = [0.50; 0.90]; p = 0.0040 < 0.01026), 2% deaths in the experimental group versus 20.5% patients in the control group. The median OS was not reached in either of the two groups.
And despite:
- the absence of any formal conclusion that can be drawn based on the quality of life findings;
- a safety profile deemed to be acceptable compared to chemoradiotherapy but marked by an excess toxicity with grade ≥ 3 AEs reported in 78.3% of patients in the pembrolizumab group and 70.0% of patients in the placebo group). In addition, 20.6% of patients in the pembrolizumab group and 14.9% of patients in the placebo group had an AE resulting in definitive discontinuation of pembrolizumab treatment.
The Committee deems that KEYTRUDA (pembrolizumab) 25 mg/ml, concentrate for solution for infusion, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), provides a moderate clinical added value (CAV III) compared to chemoradiotherapy.
|
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
kN4dQaj6assJ2EJW